PARADIGM-HF

Angiotensin-neprilysin inhibition versus enalapril in heart failure - The New England Journal of Medicine - 2014

Brief Summary:

Among patients with HFrEF, treatment with an angiotensin receptor-neprilysin inhibitor reduces CV mortality or HF hospitalizations when compared to enalapril. It is also associated with a reduction in all-cause mortality.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/25176015